INM INM
Company Profile ↓Company Overview
INM (INM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 26.9% CAGR over the past five years.
Recent Developments
- Jun 2025 Revenue of $4.94M (+7.5% YoY); net profit $-8.16M.
- Trailing 12 Months Year-on-year growth — revenue +7.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.93% |
| 1 Year: | 7.50% |
Stock Price Performance
| 1 Year: | -40.93% |
| 6 Months: | +32.08% |
| 3 Months: | +89.19% |
| 1 Month: | -16.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 43.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 276.79K | 437.31K | - | 265.09K | 309.58K | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | 111.56K | 182.28K | -491.02K | 131.16K | 192.51K | 21.24K | 324.14K | 289.46K | 493.41K | 460.89K | 175.62K | 403.16K | 184.19K | - |
| Operating Income | - | - | - | - | -2.24M | -3.10M | -2.97M | -4.28M | -3.48M | -3.51M | -2.10M | -2.00M | -2.54M | - | - | - | - | - | - | - | - |
| Net Income | -2.81M | -2.49M | -2.02M | -1.60M | -2.24M | -3.10M | -2.97M | -4.28M | -3.48M | -3.51M | -2.10M | -2.00M | -2.54M | -1.48M | -1.72M | -1.68M | -2.58M | -2.12M | -1.73M | -2.03M | -2.97M |
| Diluted EPS | - | - | - | - | - | - | -6.17 | -7.73 | -6.14 | -4.06 | -0.91 | -0.60 | -15.24 | -3.71 | -3.58 | -2.71 | -3.64 | -1.94 | -0.44 | -0.51 | -0.73 |
| R&D Expense | 1.96M | 1.61M | 1.27M | 911.16K | 937.95K | 1.77M | 1.49M | 2.54M | 1.75M | 1.38M | 851.36K | 878.30K | 1.29M | 609.79K | 656.76K | 700.14K | 895.18K | 425.37K | 581.61K | 630.64K | 1.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 1.90M | 1.37M | 4.14M | 4.60M | 4.94M |
| Gross Profit | - | - | 543.55K | 1.40M | 1.10M | 1.71M |
| Operating Income | - | -10.20M | -18.60M | -7.95M | - | - |
| Net Income | -8.94M | -10.20M | -18.60M | -7.95M | -7.68M | -8.16M |
| Diluted EPS | - | -37.96 | -33.17 | -3.25 | -20.14 | -8.36 |
| R&D Expense | 5.81M | 5.34M | 7.28M | 3.73M | 3.22M | 2.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.80M | 9.78M | 12.79M | 14.11M | 11.82M | 15.58M |
| Total Equity | 14.24M | 5.88M | 7.38M | 9.08M | 12.09M | 9.21M | 13.43M |
| Cash & Equivalents | 9.84M | 5.81M | 7.36M | 6.18M | 8.91M | 6.57M | 11.08M |
| Total Liabilities | - | 1.92M | 2.40M | 3.71M | 2.02M | 2.62M | 2.15M |
| Current Liabilities | - | 1.68M | 2.22M | 3.32M | 2.00M | 1.97M | 1.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.37M | -9.79M | -15.58M | -7.28M | -6.99M | -7.77M |
| Investing Cash Flow | 3.79M | -1.73K | -673.00K | -661.80K | -9.29K | - |
| Financing Cash Flow | -30.99K | 10.85M | 15.07M | 10.68M | 4.65M | 12.27M |
| Capital Expenditure | -42.57K | -1.73K | -39.11K | -160.01K | -9.29K | - |
| Free Cash Flow | -7.42M | -9.79M | -15.62M | -7.44M | -7.00M | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 39.8% | 33.9% | 23.9% | 34.5% |
| Operating Margin % | - | -535.9% | -1,361.9% | -192.2% | - | - |
| Net Margin % | - | -535.9% | -1,361.9% | -192.2% | -166.9% | -165.1% |
| ROE % | -152.1% | -138.3% | -204.9% | -65.7% | -83.4% | -60.8% |
| ROCE % | - | -134.9% | -196.5% | -65.7% | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INM
Mentari Says $200M Financing Extends Cash Runway Into 2029 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOUDhsaWRHRHUtVVJxUTZ6X1ZWU1huSWVzRmxZdzIyY2NpSXJicHd3RGRBOGlZOUVSOFZEM1Bld0ZZbklQMUZZRk5vUVJraUxqbDJ3Ti1sV00yWW5fOEVIZnlFUVZxYnNJRVVzVDRmSXFkNTY0UThnRzBVaEZyVWhYWEtkaFVqNXhsM2NnUz…
INM Stock Whipsaws As InMed Refines Mentari Merger Terms - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQYmVPal9PaE05c1pkWG9rb1A5Ymtfb0g5WXhnUnV3SUNBN2NoRlpiM1lYRzVnTko4ZHJ4cnZHWTRIODZwa0dxWlRBQ3dTVXFmMnF0MXR0azRlQ25XUjNRcXZOVXQ3WmpGRmdWSWhYeXEtNVpnQTd3ZnFROEQ3OW5uWVZoZHVHZw?oc=5" t…
$INM stock is up 34% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPc21IRDJsN2ptY3FWbTRPdjl0a01vNm85LW1PVGZobHBSb0tWbUVva1ZaRWM1bGZrMXpjQUhLM3hxbHA5Tm9Kc3ctQkpPOXJpdS1Cd0IzNHR5dnhjLUYzbnYzeXEtbm9QdzFhMHZoYTRNbFNaSWFLUzR0T1FUQkptNWZURTlzdE85MEpNUD…
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxQWjYyM2pXOWRSa0VrQUFRWDExVmRuRmtiQzFVaXhKSHZ3NFpCUUljWTI5Y0plMVlGSl9ZakluTUE0cW53SUxwQU04ZXo5WXUxNFhJWk9nc21mWGhnX1NOb05zQzZiMy0tVWFLMFlkTGpnQWxmVk9uNE04S3ZNSW1GSFZNYWJGSFdlTktENz…
Gapping stocks in Wednesday's session - ChartMill
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQSk1sUGU2SksxblphRWQ4VGhzbG14cFZKUzNadWRxX0dRU0EtR0F2WHlLd0FfblNiR1RVNTh6aXJJRnREelZCYnZvNEhuWHEtVXc5SHRYZXJ2cElFN1hVZjQta2JCdm1PNW9VQVNjeFZ4Zm0ycUJiSUlPTjlNZk9fUHNqMDRrQm1teVB3VU…
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - InMed Pharmaceuticals (NASDAQ:INM), Chin - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxObFg1UnNCZEVhV3hMTy1LZXpCaENkeHhTNy1nTVVFNDdRb2RZT1RIc0VKUGtNLVVsUV9MRzNQeVZfSDlURDJac0l5cGltSUljcjV1VEl3SkE3VWpRTWFlQjhpVnh1LWtmNHhzeHdPMlZGUjhpZDdkQzVDeVRROWdhanRvb1ctUXpHYnp0MH…
INM — Frequently Asked Questions
What is the current share price of INM?
As of 2026-08-05 17:25 PDT, INM trades at $1.40 on NASDAQ/NYSE. Its 52-week range is $0.62 to $2.46.
What is the P/E ratio of INM?
INM trades at a trailing price-to-earnings (P/E) ratio of -0.17.
What is the return on equity (ROE) of INM?
INM has a return on equity (ROE) of -60.76%. Its return on capital employed (ROCE) is -57.84%.
Is INM a good stock to buy?
This page provides a data-driven analysis of INM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.